Cristin-resultat-ID: 2019562
Sist endret: 17. februar 2023, 16:31
NVI-rapporteringsår: 2022
Resultat
Vitenskapelig artikkel
2022

“It was an important part of my treatment”: a qualitative study of Norwegian breast Cancer patients’ experiences with mainstreamed genetic testing

Bidragsytere:
  • Nina Strømsvik
  • Pernilla Marie A. Olsson
  • Berit Gravdehaug
  • Hilde Lurås
  • Ellen Schlichting
  • Kjersti Jørgensen
  • mfl.

Tidsskrift

Hereditary Cancer in Clinical Practice
ISSN 1731-2302
e-ISSN 1897-4287
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2022
Publisert online: 2022
Volum: 20
Hefte: 6
Open Access

Importkilder

Scopus-ID: 2-s2.0-85124741417

Beskrivelse Beskrivelse

Tittel

“It was an important part of my treatment”: a qualitative study of Norwegian breast Cancer patients’ experiences with mainstreamed genetic testing

Sammendrag

Background: In South-Eastern Norway, genetic testing for BRCA1 and BRCA2 is offered to breast cancer patients by their treating surgeon or oncologist. Genetic counselling from a geneticist or a genetic counsellor is offered only to those who test positive for a pathogenic variant or have a family history of cancer. This practice is termed "mainstreamed genetic testing". The aim of this study was to learn about patients' experience of this healthcare service. Methods: Qualitative in-depth interviews were conducted with 22 breast cancer patients who had been diagnosed during the first half of 2016 or 2017 at one regional and one university hospital and who had been offered testing by their treating physician. A six-phase thematic approach was used to analyse the data. Results: The participants had varied experiences of how and when testing was offered. Three main themes emerged from the analysis: 1. informational and communicational needs and challenges during a chaotic time, 2. the value of genetic testing and 3. the importance of standardised routines for mainstreamed genetic testing. Conclusions: Despite the shock of their diagnosis and the varying experiences they had in respect of how and when testing was offered, all of the participants emphasised that genetic testing had been an important part of their diagnosis and treatment. Our results indicate that there is a need for continuous collaboration between geneticists, surgeons, oncologists and laboratory specialists in order to establish simple and robust routines so as to ensure that all eligible breast cancer patients are offered testing at a point when the test result can have an impact on treatment. Keywords: BRCA1, BRCA2; Breast cancer; Genetic testing for breast cancer; Mainstreamed genetic testing; Qualitative study.

Bidragsytere

Nina Strømsvik

  • Tilknyttet:
    Forfatter
    ved Barne- og ungdomsklinikken ved Universitetssykehuset Nord-Norge HF
  • Tilknyttet:
    Forfatter
    ved Institutt for helse- og omsorgsvitskap ved Høgskulen på Vestlandet

Pernilla Marie A. Olsson

  • Tilknyttet:
    Forfatter
    ved Avd Kirurgi Elverum ved Sykehuset Innlandet HF

Berit Gravdehaug

  • Tilknyttet:
    Forfatter
    ved Bryst- og endokrinkirurgi ved Akershus universitetssykehus HF

Hilde Lurås

  • Tilknyttet:
    Forfatter
    ved Klinikk for helsetjenesteforskning og psykiatri ved Universitetet i Oslo
  • Tilknyttet:
    Forfatter
    ved Helsetjenesteforskning (HØKH) ved Akershus universitetssykehus HF

Ellen Schlichting

  • Tilknyttet:
    Forfatter
    ved Seksjon for bryst og endokrinkirurgi ved Oslo universitetssykehus HF
1 - 5 av 11 | Neste | Siste »